Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Double-blind, Placebo-Controlled Study to Investigate the Efficacy, Safety and Tolerability of MRG-201 Following Intradermal Injection in Subjects With a History of Keloids

Trial Profile

A Phase 2, Double-blind, Placebo-Controlled Study to Investigate the Efficacy, Safety and Tolerability of MRG-201 Following Intradermal Injection in Subjects With a History of Keloids

Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2018

At a glance

  • Drugs Remlarsen (Primary)
  • Indications Fibrosis; Keloids
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors miRagen Therapeutics
  • Most Recent Events

    • 07 Nov 2018 According to a miRagen Therapeutics media release, the company expects to report data from this clinical trial in the second half of 2019.
    • 13 Jul 2018 Planned number of patients changed to 12.
    • 10 Jul 2018 Status changed from planning to recruiting, according to a miRagen Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top